Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1558736 | 0.75 | HCAR2 (0.57) | MAPTALDH1A1HCAR2 | |
| SCHEMBL6363165 | 0.74 | HCAR2 (0.44) | MAPTHPGDSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4281475 | 0.69 | HPGD (0.53) | HTTLMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL4281243 | 0.68 | GAA (0.48) | LMNAMAPTHPGDSMN1; SMN2RAB9A | |
| SCHEMBL4006577 | 0.67 | DYRK1A (0.62) | MAPTHPGDSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL16832074 | 0.65 | HCAR2 (0.34) | HTTMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4288230 | 0.65 | LMNA (0.65) | HTTLMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL9762363 | 0.65 | KMT2A (0.46) | HTTLMNAMAPTHPGDSMN1; SMN2 | |
| SCHEMBL2050024 | 0.63 | HPGD (0.92) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL2035287 | 0.62 | HPGD (0.42) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | HTT 4201/4885LMNA 2198/4885MAPT 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.